Our story began with deep insights uncovered from truly listening to patients and healthcare providers.
The alignment, focus and dedication of our leadership team comes from a shared passion for improving the quality of health outcomes. We take pride in our engaged team who strive to bring a depth of experience, drive data-driven integrated solutions and support healthcare professionals in diagnosing patients threatened by cardiac arrhythmias, potentially preventing more serious medical events such as stroke.
Jon Otterstatter is the original co-founder of Preventice Technologies in 2007; formerly known as Preventice. He currently serves as the Chief Executive Officer since 2016. Jon earned a reputation as a creative, solutions-oriented leader and technology visionary. His skills and commitment to excellence have brought high value to global enterprises while returning above-average value for stakeholders. Prior to co-founding Preventice, Jon served as Executive Vice President and Chief Technology Officer for SPSS. While at SPSS, he guided the strategic direction, budget, personnel and daily operations for the company’s worldwide technology operations. He also served as Senior Vice President of Technology for ShowCase Corporation in Rochester, MN, and was a Senior Programming Manager at IBM. Jon holds a Master ’s degree in Technology Management from Massachusetts Institute of Technology (M.I.T.), and a Bachelor’s degree in Computer Science from the University of Wisconsin-La Crosse.
Emily Benner serves as the Executive Vice President of Technology. She joined the company in 2013. In her role, Emily leads and directs the research of future product opportunities. Emily brings over 24 years of experience to the company. She held executive roles at IBM in firmware development, development of operating systems, and strategic technical development partnerships with large multinational corporations such as SAP and Oracle. Prior to joining the company, Emily was a software director at IBM where she led large development teams of 300-500 people located in the U.S., Mexico, Germany, and India. Benner holds a Bachelor’s degree in electrical engineering from the University of North Dakota, a master ’s degree in computer engineering from the University of Minnesota, and a MBA from the University of Minnesota’s Carlson School of Management.
David Isenhour serves as the Executive Vice President of Operations and General Manager of the Houston site. He joined the company in 2018. In his role, David focuses on delivering high-quality products, technologies and services to help Preventice exceed the expectations of patients, customers, and employees every day. This team is comprised of supply management, manufacturing, supply chain, and business services. David brings over 25 years of experience to the company. Prior to joining the company, David has held executive level positions within IBM where he focused on global business development, strategic technology alliances, product management, software and hardware development, M&A and corporate logistics. He repeatedly diagnosed and created opportunities to institute new models for operating at scale and unlocking value. David holds a Master’s degree in Technology Management from MIT and Bachelor of Science in Materials Engineering from North Carolina State University.
Ryan Ranweiler serves as Chief Financial Officer, Secretary and Treasurer. He brings 20 years of senior financial leadership in mobile advertising, media and technology. In his role, Ryan is responsible for leading the finance, collections, human resources and legal teams. Prior to Preventice, Ryan served as Chief Financial Officer for Sportradar U.S., a SaaS platform delivering sports statistics worldwide. From 2005 to 2015, Mr. Ranweiler held various executive positions at NativeX, a leading mobile advertising technology provider, most recently Senior Vice President, CFO and Secretary. While at NativeX, Ryan was responsible for finance, human resources, legal and certain areas of operations and was responsible for helping deliver 9 consecutive years of positive EBITDA. Prior to joining NativeX, Ryan was a manager at Clifton Larson Allen where he provided attestation services and buy/sell-side diligence to companies in support of their M&A activities. He began his career at Grant Thornton (Minneapolis) and received a Bachelor's degree in accounting from the University of Northwestern – Saint Paul. He holds an active certified public accountant (CPA) and chartered global management accountant (CGMA) license.
Tom Sheehy serves as executive vice president (EVP) and chief commercial officer (CCO). He joined the company in 2020. In his role, Tom is responsible for leading the commercial organization, including sales, marketing, product management, corporate accounts, payer relations and healthcare solutions teams. He brings more than 20 years of experience in sales and marketing. Prior to joining Preventice, Tom spent seven years in leadership roles at Medtronic, as national senior sales director leading the integration of acquired TYRX antibiotic envelope technology, national vice president of sales, AF supporting Medtronic cryoablation technology, and senior area sales director supporting the Coronary and Diagnostics businesses. Prior to Medtronic, Tom worked in various senior sales management roles for both St. Jude Medical (now Abbott) where he won President’s Award and Guidant (now Boston Scientific) where he received the Field Clinical Engineer of the Year Award for three consecutive years. Prior to joining the medical device industry, Tom spent more than three years as a U.S. Army Engineer. Tom is also a veteran of the first gulf war-operation desert shield/storm. He received a Bachelor of Science Degree in Mechanical Engineering from the United States Military Academy, where he graduated with academic distinction, and a Master of Business Administration (MBA) from Georgia State University.
Board of Directors
Bill Taranto is President, Merck Global Health Innovation Fund LLC and Vice President, Global Health Innovation Group (GHI). Mr. Taranto is responsible for building the global health innovation (GHI) capability for Merck. The Merck Global Health Innovation (GHI) invests in emerging companies that deliver breakthrough healthcare solutions and which advance Merck's mission to discover, develop and provide innovative products and services that save and improve lives. GHI has a focused strategic investment approach designed to unlock the full value of health care innovations from around the world. As a strategic growth investor, GHI's goal is to grow emerging healthcare solutions into meaningful businesses. Established in 2010 as an independent LLC, GHI deploys its evergreen $500 million fund to rapidly identify and develop transformative global healthcare opportunities. GHI is focused on identifying opportunities that are adjacent to Merck’s core business of pharmaceuticals and vaccines. Mr. Taranto is a member of the Innovative Ventures Board, a group that manages the identification and funding of portfolio businesses; and is also head of the GHI Fund LLC Management Board. Mr. Taranto is also a board member of the Imperial College of London's Intellectual Property Research Centre. Prior to joining Merck, Mr. Taranto spent 18 years at Johnson & Johnson in various marketing, sales and business development roles with increasing responsibility. In his previous position, Executive Director, Health Care Strategy & Alliances, he was responsible for evaluating the future healthcare environment, the viability and impact of healthcare channels, and the creation of new healthcare business models. Mr. Taranto started his career as a sales representative for Janssen Pharmaceutica and progressed through various sales and marketing positions, including an assignment in Beerse, Belgium. Prior to joining Johnson & Johnson, Mr. Taranto spent eight years in investment banking. Mr. Taranto has a Bachelor of Business Administration from St. Bonaventure University.
Charlie has been Senior Vice President, Corporate Strategy and Business Development at Boston Scientific Corporation (BSC) since 2010. His team is responsible for corporate strategic planning as well as coordinating the identification, assessment and execution of business development transactions including acquisitions, VC/minority investments, divestitures, licensing deals, and joint ventures. BSC has been amongst the most active investors in medical technology over the past 10 years, having completed over 35 acquisitions across size ranges from sub $10 million to several $ billions, as well as building a venture capital portfolio of over 40 investments across strategic areas of interest. Prior to BSC, Charlie spent 16 years in investment banking in New York, Chicago, and Paris (France) at Credit Suisse First Boston / Donaldson Lufkin & Jenrette (from 1999 til 2009) and Bankers Trust /BT Alex Brown (1993-1999). Charlie grew up and went to high school in France, and received a Bachelor of Arts in Economics from Princeton University.
Joseph Siletto is a managing director with Vivo Capital where he focuses on growth equity investments and private equity transactions. Mr. Siletto has over 20 years of experience in healthcare transactions and investments as a CEO of a private company, Investment Banker and Investor. Prior to joining Vivo, he co-founded Scion Medical, a commercial-stage, China-US cross border medical device roll-up in the interventional oncology segment which Varian Medical (NYSE: VAR) acquired in 2019. Earlier in his career, Mr. Siletto was an Investment Banker for Banc of America Securities and Cowen Inc. Mr. Siletto graduated with a B.A. from Duke University, earned his MBA from the University at California at Berkeley and also studied at the Beijing Language Institute.
Jon Otterstatter is the original co-founder of Preventice Technologies in 2007; formerly known as Preventice. He currently serves as the Chief Executive Officer since 2016. Jon earned a reputation as a creative, solutions-oriented leader and technology visionary. His skills and commitment to excellence have brought high value to global enterprises while returning above-average value for stakeholders. Prior to co-founding Preventice, Jon served as Executive Vice President and Chief Technology Officer for SPSS. While at SPSS, he guided the strategic direction, budget, personnel and daily operations for the company’s worldwide technology operations. He also served as Senior Vice President of Technology for ShowCase Corporation in Rochester, MN, and was a Senior Programming Manager at IBM. Jon holds a Masters degree in Technology Management from Massachusetts Institute of Technology (M.I.T.), and a Bachelor’s degree in Computer Science from the University of Wisconsin-La Crosse.
Joe has more than two decades of experience in health care investing applying a technical engineering background coupled with an understanding of emerging technologies. He is considered to be one of the industry's leading corporate investors. In 2016, Joe was named by Global Corporate Venturing as one of the top five rising stars. Joe currently holds board seats with Aerosafe, ClearDATA, TriNetX, Prognos, Preventice, and Volansi (observer). Previously he sat on the board of Koneksa, and has exited companies: Aptus Health, Exostar, Humedica, Liaison and Remedy Informatics. Joe chairs several M&A and audit committees at these companies while holding current board seats. Joe has been instrumental in transforming Merck GHIF from a leader, not only in venture capital, but also in growth equity and M&A. He earned industry laurels when he participated in the sale of Humedica, a healthcare analytics company, to UnitedHealth Group in 2013, a transaction that produced a 17-fold return. In addition to his success with Humedica, Joe has led investments and acquisitions in companies such as AeroSafe, TriNetX, Liaison, Preventice, Physicians Interactive, Koneksa, Prognos, Volansi, WellDoc, Exostar, and ClearDATA. During this same period, he has also managed 60-plus transactions at Merck, all at various stages of maturity. Joe is also renowned for his leadership with Preventice to further develop its remote care monitoring platform for cardiac arrhythmia patients. Joe led the Merck strategy and merger of Preventice with eCardio and eventually sold a portion of the combined company to a leading healthcare channel partner, which paid back the fund for the original investment while maintaining majority share of a more valued company. Joe also focused on the patient physician engagement space with his Physicians Interactive (now called Aptus) investments. He eventually led the acquisition of the company on behalf of Merck GHIF. Joe also led the acquisitions of MedHelp, Quantia MD and Tomorrow Networks within Aptus. Joe came to Merck from Johnson and Johnson where he spent more than 20 years in innovation and investment roles across Consumer, Pharma and Device sectors of J&J. Prior to that he was a consultant with EDS where he was selected and graduated from their Top Gun business and technology program. He went to the University of South Florida where he obtained a degree in Business/Information Systems and Engineering.